# A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

> **NCT05123586** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 85 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** LY3361237
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05123586
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-07
- **Primary completion:** 2023-12-29
- **Final completion:** 2023-12-29
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Study terminated due to lack of efficacy
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05123586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05123586, "A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05123586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*